



Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Audited Financial Results for the Year ended 31st March, 2009

(Rs. in Lacs)

(Rs. in Lacs)

CONSOLIDATED RESULTS				Particulars	JUBILANT ORGANOSYS LTD			
Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)			Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)	
2009	2008	2009	2008		2009	2008	2009	2008
84124	68901	351798	248888	Net sales/Income from operations	54806	53431	243072	197675
243	283	2434	977	Other Operating Income	129	204	1138	787
84367	69184	354232	249865	Total income	54935	53635	244210	198462
79340	60110	310893	212827	Total expenditure	54495	43913	208352	160316
(1868)	(981)	(7813)	(1545)	a) (Increase)/Decrease in stock in trade and work in progress	2294	(931)	(2811)	(1623)
2418	1563	11349	5069	b) Purchase of traded goods	3339	1415	10668	4748
29138	26496	131488	95102	c) Raw & process materials consumed	23804	24777	113470	89428
5014	4547	21116	16744	d) Stores, spares, chemicals, catalyst & packing material consumed	2352	2535	11666	10669
3882	5075	19791	17043	e) Power & fuel	3462	4878	18079	16410
2202	1712	8675	5929	f) Other manufacturing expenses	1742	1457	6364	5322
17780	10830	65749	38392	g) Staff cost	3684	3063	15600	12934
4509	3610	16324	10391	h) Depreciation	2094	2066	7462	6359
7494	(231)	10429	(309)	i) Exchange Loss/(Gain)	7796	(89)	10188	(352)
8771	7489	33785	26011	j) Selling, general & admin. expenses	3928	4742	17666	16421
5027	9074	43339	37038	Operating profit before Other Income & Interest	440	9722	35858	38146
1027	512	1816	2925	Other Income	406	104	674	295
6054	9586	45155	39963	Profit before Interest & Exceptional Items	846	9826	36532	38441
3883	202	10704	3367	Interest (Net)	2722	(226)	5435	1468
2171	9384	34451	36596	Profit after Interest but before Exceptional Items	(1876)	10052	31097	36973
3692	927	4793	1289	Exceptional items	2693	927	3794	1289
(1521)	8457	29658	35307	Profit from Ordinary Activities before tax	(4569)	9125	27303	35684
(2426)	(201)	2672	5728	Tax Expenses (Net)	(3040)	845	1229	6763
905	8658	26986	29579	Net profit from Ordinary Activities after tax	(1529)	8280	26074	28921
-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-
(332)	270	(1332)	(165)	Minority Interest	-	-	-	-
1237	8388	28318	29744	Net profit after Minority Interest	(1529)	8280	26074	28921
1475	1462	1475	1462	Paid-up share capital (Face value per share Re. 1)	1475	1462	1475	1462
		125279	124150	Reserves (excluding revaluation reserve)			132463	136397
0.84	5.78	19.22	20.67	Basic (Rs.)	(1.04)	5.71	17.70	20.10
0.72	4.64	16.56	16.65	Diluted (Rs.)	(0.89)	4.58	15.25	16.19
73121834	71807890	73121834	71807890	Public shareholding	73121834	71807890	73121834	71807890
49.56	49.12	49.56	49.12	- Number of shares (Re. 1 each)	49.56	49.12	49.56	49.12
				- Percentage of shareholding				
				Promoters and promoter group Shareholding				
				a) Pledged/Encumbered				
16421000		16421000		- Number of shares	16421000		16421000	
22.07		22.07		- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	22.07		22.07	
11.13		11.13		- Percentage of shares (as a % of the total share capital of the company)	11.13		11.13	
57999424		57999424		b) Non-Encumbered	57999424		57999424	
77.93		77.93		- Number of shares	77.93		77.93	
				- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
39.31		39.31		- Percentage of shares (as a % of the total share capital of the company)	39.31		39.31	

Segment Wise Revenue, Results & Capital Employed (Under Clause 41 of the Listing Agreement)

CONSOLIDATED RESULTS				Particulars	JUBILANT ORGANOSYS LTD			
Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)			Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)	
2009	2008	2009	2008		2009	2008	2009	2008
60101	46085	232370	153015	Segment revenue				
				a. Pharmaceuticals and Life Science Products & Services	31042	30623	123619	102065
24087	22999	119751	96284	b. Industrial & Performance Products	23828	22991	119776	96021
84188	69084	352121	249299	Total	54870	53614	243395	198086
64	183	323	411	Less : Inter segment revenue	64	183	323	411
84124	68901	351798	248888	Net sales/Income from operations	54806	53431	243072	197675
60101	46085	232370	153015	a. Pharmaceuticals and Life Science Products & Services	31042	30623	123619	102065
24023	22816	119428	95873	b. Industrial & Performance Products	23764	22808	119453	95610
84124	68901	351798	248888	Total	54806	53431	243072	197675
9809	8649	42224	30355	Segment results (profit(+)/loss(-) before tax and interest from each segment)				
				a. Pharmaceuticals and Life Science Products & Services	4609	9348	33698	31305
165	1744	10930	12889	b. Industrial & Performance Products	170	1751	11035	12922
9974	10393	53154	43244	Total	4779	11099	44733	44227
3883	202	10704	3367	Less : i. Interest	2722	(226)	5435	1468
13923	2301	19636	7352	ii. Other un-allocable expenditure	12927	2289	18577	7331
(6311)	(567)	(6844)	(2782)	iii. Un-allocable Income	(6301)	(89)	(6582)	(256)
(1521)	8457	29658	35307	Total profit before tax	(4569)	9125	27303	35684
409275	237731	409275	237731	Capital Employed (Segment assets less Segment liabilities)				
				a. Pharmaceuticals and Life Science Products & Services	127119	112827	127119	112827
75248	68141	75248	68141	b. Industrial & Performance Products	75002	68141	75002	68141
484523	305872	484523	305872	Total Capital employed in segments	202121	180968	202121	180968
44744	45755	44744	45755	Add: Un-allocable corporate assets less liabilities	197037	137718	197037	137718
529267	351627	529267	351627	Total capital employed in the Company	399158	318686	399158	318686

Notes:

- The Company has opted for accounting the exchange difference arising on reporting of long term foreign currency monetary items in line with the Companies (Accounting Standard) Amendment Rules 2009 on AS 11 notified by the Ministry of Corporate Affairs on 31st March 2009. Accordingly, the company has capitalized exchange difference amounting to Rs.11308 lacs to the cost of fixed assets and the balance amount Rs.15960 lacs (Consolidated Rs.27509 lacs) transferred to Foreign Currency Monetary Item Translation Difference Account. The exchange gain amounting to Rs.10306 lacs credited to Profit & loss account in the previous year is now reversed through General Reserve. Accordingly the results for the previous periods/year were recasted and reported to reflect the said changes.
- Exceptional items for the year include :
 - Gain of Rs.5907 lacs on buyback of Foreign Currency Convertible Bonds of US \$60.90 million due in FY 2011 and FY 2012.
 - Provision of loss of Rs.9429 lacs (Consolidated Rs. 10130 lacs) on mark to market of unutilized forward covers outstanding as on 31st March 2009.
- Tax expense is net of deferred tax credit and applicable MAT credit entitlements.
- Jubilant Employee Welfare Trust purchased 5,371,747 equity shares of the Company from the open market, out of loan provided by the Company.
- The Board has recommended a dividend of Rs.1.50 per equity share of Re.1 totaling to Rs.2589.25 lacs, subject to approval in Annual General Meeting.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New - 24, Disposals - 24, Closing Balance - Nil.
- Previous year figures are not comparable due to acquisition of Draxis Health Inc. Canada and Specialty Molecules Ltd during the year. Figures for previous period / year have been regrouped / reclassified / restated, wherever considered necessary.
- The above Financial Results were taken on record by the Board of Directors at the meeting held on 28th April, 2009.

For Jubilant Organosys Ltd.

Place : Noida
Dated : 28th April, 2009

Shyam S Bhartia
Chairman & Managing Director